gene editing

CRISPR/Cas9 technology in oncology: mechanisms, applications, and future perspectives

The mechanisms of CRISPR/Cas action and its applications in hematologic malignancies, breast cancer, colorectal cancer, gastric cancer, and lung cancer are explored.

Genome Editing in Solanaceae: Harnessing CRISPR-Cas Technology for Precision Crop Improvement

This review synthesizes recent advances, identifies critical limitations, and outlines future opportunities for deploying CRISPR/Cas technology to achieve next-generation breeding and food system resilience.

Genetherapy in neurological disorders

Toward a Precision Cure for Chronic Hepatitis B: Convergence of RNA Silencing, Gene Editing, Immune-Reset Therapies, and Artificial Intelligence-Guided Diagnostics

Chronic hepatitis B virus (HBV) infection remains a major global health challenge, affecting over 250 million individuals and causing more than one million deaths annually from cirrhosis and hepatocellular carcinoma. Although current antiviral therapies effectively suppress viral replication, they rarely achieve a func...

Supplementary Datasets underlying analysis and results presented inCRISPR-enhanced assessment of variants of unknown significance nominates oncology therapeutic targets and drug repositioning opportunities. Savino et Al. 2026

The functional interpretation of infrequent somatic variants remains a challenge in cancer genomics. We developed CRISPR-VUS, a computational framework using public Cancer Dependency Map data to identify Dependency-Associated Mutations (DAMs) - somatic variants associated with increased dependency on their host genes -...

Common variant-based genome editing to address the heterogeneity of pathogenic variants in dominant disorders

The Evolving Landscape of Drug Discovery for Hepatitis B: Recent Advances and Future Prospects

The main cause of Hepatocellular Carcinoma and Liver Cirrhosis is an infection due to Hepatitis B virus (HBV) which remains a major global health concern. A complete cure with the help of Current therapies is very difficult due to the persistence of covalently closed circular DNA (cccDNA) although pegylated interferons...

Precision Medicine in Viral Hepatitis: Current Advances, Challenges and Future Perspectives

Viral hepatitis is a major global health problem, being the leading cause of chronic liver disease, cirrhosis, and hepatocellular carcinoma. The World Health Organization (WHO) has reported that hepatitis B and C viruses cause 1.34 million deaths yearly, and despite the availability of effective vaccines and treatments...

Vaccines, Drug Development, and Novel Therapeutic Strategies for Hepatitis: Current Advances and Future Perspectives

Despite remarkable progress in prevention and treatment, hepatitis is still one of the main drivers of chronic liver disease, liver cirrhosis and hepatocellular carcinoma and is a big public health problem worldwide. The hepatitis viruses A, B, C, D and E are responsible for the occurrence of viral hepatitis in million...

Gene-edited pig kidney transplant sets record—and offers bridge to human organs

The Evolving Landscape of Drug Discovery for Hepatitis B: Recent Advances and Future Prospects

The main cause of Hepatocellular Carcinoma and Liver Cirrhosis is an infection due to Hepatitis B virus (HBV) which remains a major global health concern. A complete cure with the help of Current therapies is very difficult due to the persistence of covalently closed circular DNA (cccDNA) although pegylated interferons...

A new MRR1 gain-of-function mutation involved in cross-resistance to antifungal agents in the fungal priority pathogen Candida parapsilosis.

The findings reinforce the central role of Mrr1 in antifungal resistance, underscore the functional diversity of its mutational landscape, and underscore the functional diversity of its mutational landscape, with potential implications for fungal fitness and transcriptional regulation.